b | Recombinant ACE2 protein could be a potential therapeutic agent to prevent or treat COVID-19

On By msisig

b | Recombinant ACE2 protein could be a potential therapeutic agent to prevent or treat COVID-19. from your European Renal Association COVID-19 Database (ERACODA) demonstrated no significant association between previous use or continuation of RAS blockade and 28-day mortality among patients on dialysis and kidney transplant recipients with COVID-19 after adjustment for baseline demographics, comorbidities and COVID-19 severity3. In addition, RAS blockade was not associated with a substantially increased risk of hospital admission, rigorous care unit admission or need for ventilator support in these patients. This study indicates that RAS blockade can be safely continued in patients with kidney failure and COVID-19. The role of ACE2 in SARS-CoV-2 contamination has also led to investigation of this receptor as a potential therapeutic target. As SARS-CoV-2 binds to membrane-bound full-length ACE2, Wysocki et al. investigated whether a truncated form of human soluble ACE2 could be used as a decoy receptor to limit viral contamination4. The truncated protein (ACE2 1-618) was fused with an albumin-binding domain name (ABD) to increase its duration of action. In mice, plasma ACE2 1-618CABD experienced substantial Igf1r catalytic activity 96?h after injection and remained biologically active (that is, retained its ability to lower blood pressure when given 3 days before angiotensin II injection). Wysocki et al. also showed that human kidney organoids express both full-length ACE2 and TMPRSS2 protease, which is required for fusion and internalization of the ACE2CSARS-CoV-2 viral spike protein complex. ACE2 1-618CABD neutralized SARS-CoV-2 contamination in these organoids. In a preprint, the experts demonstrate that treatment with a dimeric version of the ACE2 1-618CABD construct (ACE2 1-618CDDD-ABD) guarded a transgenic mouse model of lethal SARS-CoV-2 contamination from developing severe disease5. A case statement6 of successful treatment of a patient with severe COVID-19 using full-length soluble recombinant human ACE2 (rhACE2) was published in 2020, and this therapy is now being analyzed in a clinical trial7. Wysocki et al. suggest that their truncated ACE2 construct might be more suitable than rhACE2 for treatment of COVID-19 because of its longer duration of action and smaller size, which should enable it to be filtered by the kidney and potentially protect against LSN 3213128 COVID-19-associated kidney disease4. Vaccination is one of the most important weapons in the fight against SARS-CoV-2 Vaccination is one of the most important weapons in the fight against SARS-CoV-2. Patients on dialysis and kidney transplant recipients often have impaired immune responses and therefore require higher and more frequent vaccine doses than the general populace. In 2021, Bensouna et al. analyzed the humoral response to a third dose of the BNT162b2 mRNA COVID-19 vaccine among patients on haemodialysis or peritoneal?dialysis ( em n /em ?=?69)8. They statement that administration LSN 3213128 of a third vaccine dose increased the levels of anti-SARS-CoV-2 spike protein S1 (anti-S1) antibodies from a median of 284 (interquartile range, 83C1,190) arbitrary models/mL at a median of 50 days after the second dose to a median of 7,554 (interquartile LSN 3213128 range, 2,268C11,736) arbitrary models/mL at a median of 30 days after the third dose. The vaccine reactions were acceptable and overall self-reported tolerance to the third dose was comparable to that of the second dose. LSN 3213128 The greatest increases in antibody levels following a third dose of the BNT162b2 vaccine were seen in patients who experienced lower antibody levels after the second dose and longer intervals between the second and third doses. By contrast, little evidence of an increase in antibody level after the third dose was seen in patients who experienced high anti-S1 antibody levels after the second dose or in those who were undergoing chemotherapy. Other factors that were associated with a poor antibody response after three doses of vaccine included a history of immunosuppressive therapy or haemopathy, lower serum -globulin and initial lower anti-S1 antibodies after two doses. These results suggest that booster SARS-CoV-2 vaccine administration in patients on dialysis should be individualized depending on the initial anti-S1 antibody levels after the second vaccine dose. Following the acute phase of COVID-19, some patients develop post-COVID-19 syndrome (also known as.